Everett E. Vokes

639 total citations
19 papers, 379 citations indexed

About

Everett E. Vokes is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Everett E. Vokes has authored 19 papers receiving a total of 379 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 5 papers in Surgery. Recurrent topics in Everett E. Vokes's work include Lung Cancer Treatments and Mutations (6 papers), Lung Cancer Research Studies (5 papers) and Head and Neck Cancer Studies (4 papers). Everett E. Vokes is often cited by papers focused on Lung Cancer Treatments and Mutations (6 papers), Lung Cancer Research Studies (5 papers) and Head and Neck Cancer Studies (4 papers). Everett E. Vokes collaborates with scholars based in United States and China. Everett E. Vokes's co-authors include Ralph R. Weichselbaum, Daniel J. Haraf, William R. Panje, Ann M. Mauer, Ezra E.W. Cohen, Neil Mehta, Samuel Hellmän, Ralph R. Weichselbaum, Mark W. Lingen and Philip P. Connell and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and The American Journal of Medicine.

In The Last Decade

Everett E. Vokes

19 papers receiving 372 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Everett E. Vokes United States 11 202 172 91 88 63 19 379
C. Grafton Canada 9 349 1.7× 242 1.4× 50 0.5× 141 1.6× 41 0.7× 18 531
Jean-François Rosier Belgium 11 149 0.7× 154 0.9× 65 0.7× 89 1.0× 135 2.1× 14 389
G.K. Rath India 9 86 0.4× 110 0.6× 147 1.6× 47 0.5× 33 0.5× 34 339
Lawrence Einhorn United States 9 353 1.7× 417 2.4× 167 1.8× 95 1.1× 34 0.5× 21 700
Nathalie Syz France 5 283 1.4× 292 1.7× 102 1.1× 62 0.7× 85 1.3× 5 490
Loredana Costa Italy 11 176 0.9× 202 1.2× 124 1.4× 68 0.8× 215 3.4× 29 496
V. Barley United Kingdom 9 120 0.6× 97 0.6× 131 1.4× 42 0.5× 35 0.6× 15 453
Vitune Vongtama United States 14 105 0.5× 171 1.0× 195 2.1× 56 0.6× 36 0.6× 25 595
D. Dodwell United Kingdom 10 249 1.2× 105 0.6× 95 1.0× 67 0.8× 11 0.2× 14 393
Humera Khurshid United States 11 190 0.9× 137 0.8× 80 0.9× 70 0.8× 12 0.2× 24 342

Countries citing papers authored by Everett E. Vokes

Since Specialization
Citations

This map shows the geographic impact of Everett E. Vokes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Everett E. Vokes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Everett E. Vokes more than expected).

Fields of papers citing papers by Everett E. Vokes

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Everett E. Vokes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Everett E. Vokes. The network helps show where Everett E. Vokes may publish in the future.

Co-authorship network of co-authors of Everett E. Vokes

This figure shows the co-authorship network connecting the top 25 collaborators of Everett E. Vokes. A scholar is included among the top collaborators of Everett E. Vokes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Everett E. Vokes. Everett E. Vokes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Thawani, Rajat, Christine M. Bestvina, Everett E. Vokes, & Aditya Juloori. (2025). Rationale for Investigation of Neoadjuvant Chemoimmunotherapy Before Chemoradiation in Unresectable Stage III Non–Small Cell Lung Cancer. Journal of Clinical Oncology. 43(18). 2039–2043. 1 indexed citations
2.
Liu, Xu, Yuan Zhang, Wen‐Fei Li, et al.. (2021). Evaluation of Oncology Trial Results Reporting Over a 10-Year Period. JAMA Network Open. 4(5). e2110438–e2110438. 15 indexed citations
3.
Posadas, Edwin M., Samir D. Undevia, James L. Wade, et al.. (2007). A phase II study of ixabepilone (BMS-247550) in metastatic renal-cell carcinoma. Cancer Biology & Therapy. 6(4). 490–493. 18 indexed citations
4.
Connell, Philip P., et al.. (2006). Pilot study examining tumor expression of RAD51 and clinical outcomes in human head cancers. International Journal of Oncology. 28(5). 1113–9. 66 indexed citations
5.
Mehta, Neil, Ann M. Mauer, Samuel Hellmän, et al.. (2004). Analysis of further disease progression in metastatic non-small cell lung cancer: Implications for locoregional treatment. International Journal of Oncology. 25(6). 1677–83. 91 indexed citations
6.
Lad, Thomas E., et al.. (2000). Phase II Trial of Aminocamptothecin (9-AC/DMA) in Patients with Advanced Squamous Cell Head and Neck Cancer. Investigational New Drugs. 18(3). 261–263. 13 indexed citations
7.
Vokes, Everett E., Ann M. Mauer, Charles M. Rudin, et al.. (2000). A Phase I Study of STEALTH® Cisplatin (SPI-77) and Vinorelbine in Patients with Advanced Non–Small-Cell Lung Cancer. Clinical Lung Cancer. 2(2). 128–132. 12 indexed citations
8.
Samuels, Brian L., et al.. (1999). Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced biliary carcinoma. Investigational New Drugs. 17(1). 97–101. 24 indexed citations
9.
Vokes, Everett E., et al.. (1999). A Phase I study of raltitrexed and paclitaxel given every 3 weeks to patients with solid tumors. Cancer. 86(3). 528–532. 4 indexed citations
10.
Mick, Rosemarie, Everett E. Vokes, Timothy M. Lestingi, et al.. (1996). Etoposide combined with interferon alfa-2b: Novel exploitation of established etoposide pharmacokinetics and pharmacodynamics*. Clinical Pharmacology & Therapeutics. 59(3). 349–359. 1 indexed citations
11.
Weichselbaum, Ralph R., et al.. (1995). Timing and sequencing of chemoradiotherapy. Cancer treatment and research. 74. 173–198. 2 indexed citations
12.
Kobayashi, Yukio, et al.. (1994). A phase I study of intermittent infusion cladribine in patients with solid tumors. Cancer. 74(1). 168–173. 14 indexed citations
13.
Vokes, Everett E., et al.. (1994). Chemotherapy, biologies, and chemoprevention as systemic therapies for head and neck cancer. Current Opinion in Oncology. 6(3). 277–284. 2 indexed citations
14.
Vokes, Everett E., et al.. (1993). Escalating doses of interferon alpha-2A with cisplatin and concomitant radiotherapy: a phase I study. Cancer Chemotherapy and Pharmacology. 33(3). 203–209. 8 indexed citations
15.
Vokes, Everett E., et al.. (1992). Concomitant chemoradiotherapy with cisplatin, 5‐fluorouracil and hydroxyurea in poor‐prognosis head and neck cancer. The Laryngoscope. 102(6). 630–636. 23 indexed citations
16.
Stadler, Walter M., et al.. (1992). Continuous-infusion fluorodeoxyuridine with leucovorin and high-dose interferon: a phase II study in metastatic renal-cell cancer. Cancer Chemotherapy and Pharmacology. 31(3). 213–216. 7 indexed citations
17.
Vokes, Everett E., et al.. (1991). Survival and Analysis of Failure Following Hydroxyurea, 5-Fluorouracil and Concomitant Radiation Therapy in Poor Prognosis Head and Neck Cancer. American Journal of Clinical Oncology. 14(5). 419–426. 28 indexed citations
18.
Vokes, Everett E., Srinivasan Vijayakumar, Jacob D. Bitran, Philip C. Hoffman, & Harvey M. Golomb. (1990). Role of systemic therapy in advanced non-small-cell lung cancer. The American Journal of Medicine. 89(6). 777–786. 10 indexed citations
19.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by C. Grafton Breakdown of academic impact, for papers by Jean-François Rosier Breakdown of academic impact, for papers by G.K. Rath Breakdown of academic impact, for papers by Lawrence Einhorn Breakdown of academic impact, for papers by Nathalie Syz Breakdown of academic impact, for papers by Loredana Costa Breakdown of academic impact, for papers by V. Barley Breakdown of academic impact, for papers by Vitune Vongtama Breakdown of academic impact, for papers by D. Dodwell Breakdown of academic impact, for papers by Humera Khurshid
Rankless by CCL
2026